Compare Crispr Therapeutics AG (CRSP) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nerdwallet Inc — how do they compare? Crispr Therapeutics AG trades at $53.77 (market cap $4.88B), while Nerdwallet Inc trades at $9.83 (market cap $625.17M). The key difference: Crispr Therapeutics AG is far larger — about 7.8× Nerdwallet Inc's market cap, and Crispr Therapeutics AG is more actively traded (2,861,747 versus 1,321,316). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Nerdwallet Inc for 45 Days on average.
| CRSP | NRDS | |
|---|---|---|
Market Cap | $4.88B | $625.17M |
Volume | 2,861,747 | 1,321,316 |
Sector | Health | Media |
52-Week High | $74.92 | $15.93 |
52-Week Low | $44.34 | $7.58 |
Typical Hold Time | 77 Days | 45 Days |
Enterprise Value | $3.30B | $539.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
NerdWallet (NRDS) trades at $9.82, up 8.04% with strong technical momentum. The company shows improving fundamentals with 2025 revenue reaching $836.6M and net income of $48.7M, representing a 5.82% margin. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. Valuation metrics appear attractive with P/E of 10.87 and P/S of 0.81. Analyst sentiment remains positive with 66.7% buy ratings and technical indicators signaling bullish momentum.
The outlook remains constructive as NerdWallet demonstrates revenue growth acceleration and margin expansion. Key risks include organic search pressure in credit card products and macroeconomic sensitivity. With strong cash flow generation and institutional support, the stock offers growth potential at reasonable valuations, though investors should monitor competitive pressures and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
